Last updated 44 days ago

A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of Exacerbations

516 patients around the world
Available in Spain, Chile, Argentina, United States
This is a Phase II, randomised, placebo-controlled, double-blind, dose range-finding, multi-centre study to assess the efficacy and safety of inhaled AZD8630 administered at 3 doses via an inhaler in adult patients with uncontrolled asthma, at risk of an exacerbation. The study duration up to 57 weeks for participants in the optional safety extension study and up to 17 weeks for those not included. The maximal treatment period is up to 52 weeks. This study will be conducted in approximately 220 centres in 20-25 countries. Approximately 516 patients will be randomised globally
AstraZeneca
516Patients around the world

This study is for people with

Asthma

Requirements for the patient

To 80 Years
All Gender

Medical requirements

LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy